ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO1076

Sleeping Pills and Risk of CKD? A Nationwide Population-Based Retrospective Cohort Study

Session Information

Category: CKD (Non-Dialysis)

  • 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Liao, Chen-Yi, Tri-service general hospital, Taipei city, Taiwan
  • Wu, Chia-chao, Tri-Service General Hospital, Taipei, Taiwan
Background

Sleeping disorder has long been connected with chronic kidney disease (CKD). But the correlation between sleeping pills and CKD has not been in-depth exploration. This study aimed to evaluate the potential harm of sleeping pills on the risk for CKD and CKD progression to dialysis-requiring end-stage renal disease (ESRD).

Methods

In a population-based cohort study of 204,176 sleeping pill users within 989,753 individuals, after exclusion criteria (those with sleeping pills use less than 3 months, with acute kidney injury,CKD and ESRD diagnosis before sleeping pills use , with obstructive sleep apnea and non-apnea sleep disorder, with age less than 18 years and gender unkown), a total of 183,321 sleeping pills users were compared to 366,642 individuals without sleeping pills use followed up for 13 years after been diagnosed as CKD (ICD-9-CM). Using propensity score matching, we analyzed the type of sleeping pills related to risk of CKD and CKD progression to ESRD by Cox proportional hazards regression with adjustment for sex, age, and comorbidities.

Results

Sleeping pills use was associated with increased risk for CKD after adjusting underlying comorbidities (aHR 2.002, 95% CI 1.790-2.333, p <0.001). Despite high social economic status (insured premium more than 35,000 Taiwanese dollars) and those with hyperlipidemia, those with sleeping pills use among most comorbidities are correlated with risk of CKD. Persistent use of sleeping pills after CKD also increased the risk of concurrent ESRD (aHR 7.981, 95% CI 5.117-10.986, p <0.001). After subgroup analyzing for sleeping pill use, flurazepam (p=0.198), lorazepam (p=0.051) and triazolam (p=0.125) are the drugs with no significance in correlation to CKD risk increasing.

Conclusion

Sleeping pills use was associated with increased risk of CKD and ESRD. Further studies are warranted to confirm these findings.